ID   ZR-75-1 PDGFRA clone 30
AC   CVCL_E4X4
SY   ZR-PDGFRA 30
DR   CancerTools; 154633
RX   PubMed=19966015;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_41774; Tamoxifen.
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:8804; PDGFRB.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=19966015; DOI=10.1677/ERC-09-0062;
RA   van Agthoven T., Sieuwerts A.M., Meijer D., Meijer-van Gelder M.E.,
RA   van Agthoven T.L.A., Sarwari R., Sleijfer S., Foekens J.A.,
RA   Dorssers L.C.J.;
RT   "Selective recruitment of breast cancer anti-estrogen resistance genes
RT   and relevance for breast cancer progression and tamoxifen therapy
RT   response.";
RL   Endocr. Relat. Cancer 17:215-230(2010).
//